Volkswagen’s View of What Soaring Energy Prices Mean for the Road

2022 Energy prices have soared, making it costly to heat homes and other indoor areas. With winter quickly approaching, many Europeans are bracing for a difficult season. According to German automotive giant Volkswagen, these energy costs are also severely impacting electric vehicle production on the continent.

Michael Davies, Founder of Green Econometrics breaks down all that goes into EV production and explains the reasons behind Volkswagen’s outlook.

 

Michael’s Thoughts

“Hi, I’m Mike Davies. I’m an analyst with Green Econometrics. I’m here today to briefly talk about VW brand Chief Executive Officer Thomas Shaffer, discussing why EV production in the EU, and specifically in Germany, where VW has initiated groundbreaking for a battery production plant, Germany becomes unviable.

Simply put, it could just be posturing rhetoric. EVs are the largest energy and production transformation in history, EV production is extremely costly with investments in the billions of dollars. It’s complex. EV battery cell technology is nascent and somewhat elusive. There’s a lack of skilled labor and workforce.

There are supply chain constraints and limited battery material sourcing. Battery production is process intensive not to mention to scale the production from hundreds of thousands to tens of millions of batteries. There’s also the risk that the technology itself could change and become obsolete. The EU has limited battery production and negligible EV battery supply materials, so it makes the situation somewhat complex.

Also, EV battery production technology is changing with sodium ion battery approaches, VW has a lot on the table here. VW does have relationships with CATL, the largest battery producer in China, and has an investment in QuantumScape which is applying solid-state lithium metals for battery production.

VW should be recognized that they see that battery production is itself, gotta be vertically integrated and is of tremendous importance to their viability. Thanks.”

 

Article written by Gabrielle Bejarano.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More